Grifols (GRFS) Non-Current Assets (2009 - 2025)
Grifols (GRFS) posted Non-Current Assets of $17.0 billion for Q4 2025, up 1.71% quarter-over-quarter from $16.8 billion in Q4 2024, and up 1.71% year-on-year from $16.8 billion in Q4 2024.
Grifols (GRFS) Non-Current Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Non-Current Assets for 16 consecutive years, with $17.0 billion the latest figure, recorded in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $17.0 billion, up 1.71% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.0 billion (up 1.71% YoY), and the FY2025 annual result was $17.0 billion, up 31454.2% from the prior year.
- Non-Current Assets was $17.0 billion for Q4 2025 at Grifols, up from $16.8 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $17.0 billion in Q4 2025 and troughed at $15.7 billion in Q4 2021.
- Average Non-Current Assets over 5 years is $16.5 billion, with a median of $16.8 billion recorded in 2024.
- Year-over-year, Non-Current Assets increased 8.73% in 2021 and dropped 5.24% in 2023.
- Over 5 years, Non-Current Assets stood at $15.7 billion in 2021, then advanced by 7.48% to $16.9 billion in 2022, then slipped by 5.24% to $16.0 billion in 2023, then increased by 4.77% to $16.8 billion in 2024, then rose by 1.71% to $17.0 billion in 2025.
- Per Business Quant data, the three most recent Non-Current Assets figures were $17.0 billion in Q4 2025, $16.8 billion in Q4 2024, and $16.0 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 17.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.04 Bn |
| Dec 31, 2024 | 16.75 Bn |
| Dec 31, 2023 | 15.99 Bn |
| Dec 31, 2022 | 16.87 Bn |
| Dec 31, 2021 | 15.70 Bn |
| Dec 31, 2020 | 14.44 Bn |
| Sep 30, 2020 | 14.02 Bn |
| Mar 31, 2020 | 13.50 Bn |
| Dec 31, 2019 | 11.27 Bn |
| Sep 30, 2019 | 11.55 Bn |
| Mar 31, 2019 | 11.25 Bn |
| Dec 31, 2018 | 10.27 Bn |
| Sep 30, 2018 | 10.18 Bn |
| Jun 30, 2018 | 10.13 Bn |
| Mar 31, 2018 | 9.72 Bn |
| Dec 31, 2017 | 9.39 Bn |
| Jun 30, 2017 | 9.09 Bn |
| Dec 31, 2016 | 7.57 Bn |
| Sep 30, 2016 | 7.38 Bn |
| Jun 30, 2016 | 7.48 Bn |